Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up
Table 2
Baseline patient characteristics and MRproADM serum measurements.
Parameter
All patients
Sepsis
Nonsepsis
Number
203
136
67
Female, (%)
79 (38.9)
56 (41.2)
23 (34.3)
n.s.
Age median, (range) (years)
64 (18-90)
65 (20-90)
62 (18-85)
n.s.
Charlson comorbidity index
2 (0-9)
2 (0-6)
2 (0-9)
n.s.
APACHE II score, median (range)
18 (2-43)
19 (4-43)
14 (2-33)
0.002
SOFA score, median (range)
9 (0-17)
9 (2-17)
8 (0-17)
n.s.
Mechanical ventilation, (%)
137 (68.2)
91 (67.9)
46 (68.7)
n.s.
Vasopressor demand, (%)
125 (61.5)
92 (67.6)
33 (49.3)
0.011
ICU days, median (range)
7 (1-137)
9 (1-137)
6 (1-45)
0.009
Death in ICU, (%)
43 (21.2)
34 (25)
9 (13.4)
0.041
Overall mortality, (%)
79 (41.1)
58 (45)
21 (33.3)
n.s.
MRproADM day 1, median (range) (nmol/L)
1.48 (0.1-35.2)
3.2 (0.1-35.2)
1.1 (0.1-8.7)
<0.001
For quantitative variables, median and range (in parenthesis) are given. Abbreviations: APACHE: acute physiology and chronic health evaluation; ICU: intensive care unit; MRproADM: midregional proadrenomedullin; SOFA: sequential organ failure assessment. Significance between sepsis and nonsepsis patients was assessed using the Mann–Whitney test, Fisher’s exact test, or chi-squared test, respectively.
